Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.
Menu

Prime Medicine Inc (PRME)

Prime Medicine Inc (PRME)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Prime Medicine Reports Full Year 2025 Financial Results and Provides Business Updates GlobeNewswire - Tue Mar 3, 7:00AM CST

-- On track to file IND and/or CTA for Wilson Disease and AATD programs in 1H 2026 and mid-2026, respectively; initial clinical data for both expected in 2027 -- -- Ongoing engagement with FDA for...

PRME : 3.48 (+10.48%)
Prime Medicine to Participate in Upcoming Investor Conferences GlobeNewswire - Wed Feb 25, 7:00AM CST

CAMBRIDGE, Mass., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies,...

PRME : 3.48 (+10.48%)
Prime Medicine to Present at 44th Annual J.P. Morgan Healthcare Conference GlobeNewswire - Wed Jan 7, 7:00AM CST

CAMBRIDGE, Mass., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies,...

PRME : 3.48 (+10.48%)
Prime Medicine Announces The New England Journal of Medicine Publication of PM359 Clinical Data for the Treatment of Chronic Granulomatous Disease GlobeNewswire - Sun Dec 7, 2025

CAMBRIDGE, Mass., Dec. 07, 2025 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies,...

PRME : 3.48 (+10.48%)
Prime Medicine to Present at 8th Annual Evercore Healthcare Conference GlobeNewswire - Tue Nov 25, 2025

CAMBRIDGE, Mass., Nov. 25, 2025 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies,...

PRME : 3.48 (+10.48%)
Prime Medicine to Present at Jefferies Global Healthcare Conference GlobeNewswire - Tue Nov 11, 2025

CAMBRIDGE, Mass., Nov. 11, 2025 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies,...

PRME : 3.48 (+10.48%)
CORRECTION - Prime Medicine Reports Third Quarter 2025 Financial Results and Provides Business Updates GlobeNewswire - Fri Nov 7, 2025

-- New preclinical data for PM577 in Wilson’s Disease (WD) to be presented at AASLD; on-track to file IND and/or CTA in H1’26, with initial clinical data expected in 2027 --  -- Nominated PM647...

PRME : 3.48 (+10.48%)
Prime Medicine Reports Third Quarter 2025 Financial Results and Provides Business Updates GlobeNewswire - Fri Nov 7, 2025

-- New preclinical data for PM577 in Wilson’s Disease (WD) to be presented at AASLD; on-track to file IND and/or CTA in H1’26, with initial clinical data expected in 2027 --  -- Nominated PM647...

PRME : 3.48 (+10.48%)
Prime Medicine Appoints Matthew Hawryluk, Ph.D., M.B.A. as Chief Business Officer GlobeNewswire - Mon Nov 3, 2025

CAMBRIDGE, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies,...

PRME : 3.48 (+10.48%)
Prime Medicine to Host Virtual KOL Event to Showcase Wilson’s Disease Strategy GlobeNewswire - Thu Oct 30, 2025

CAMBRIDGE, Mass., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies,...

PRME : 3.48 (+10.48%)

Barchart Exclusives

This Dividend King Is Down 26%. When Will It Bounce Back? Barchart - Tue Mar 31, 6:30PM CDT
Abbott Laboratories is down 26% from its 52-week high due to a soft quarter. With 54 consecutive years of dividend hikes and guidance calling for mid-single-digit organic sales growth plus 10% EPS expansion, the Dividend King seems discounted, but the question is, can it rebound? Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.